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1. Introduction 
The Glioblastoma (WHO grade IV astrocytoma) is the most common and malignant primary 
adult brain cancer.  The present standard treatment appears to be maximal safe resection of 
the tumor followed by irradiation and temozolomide adjuvant chemotherapy. Despite 
advances in treatment modalities, the median survival is very poor. In addition, recent 
molecular and genetic profiling studies using various genomic technologies have identified 
several markers and unique signatures as prognostic and predictive factors of GBM.  
However, none of them are translated into clinics.  Thus with a requirement of additional 
more potent markers, proteomics appears to be more promising in particular for reasons 
like transcript levels does not correlate with protein levels due to variety of reasons like 
differences in translation efficiency, protein stability and miRNA regulation. The 
conventional methods like 2-dimensional gel electrophoresis have been in use for nearly last 
few decades. However, our ability to identify the proteins through mass spectrometry 
created renewed interest in proteomics. It is anticipated that the technological advancements 
happening in proteomics like gel free high throughput quantitative methods is going to 
revolutionize the biomarker discovery for classification, prognosis, monitoring treatment 
response and novel targets for better treatment besides understanding of glioma biology.   
2. Why proteomics is essential? 
The foundation stone for our understanding that cancer is a genetic disease and it arises due 
to changes in genes or gene activity was laid down by the field of tumor virology (Javier and 
Butel, 2008). Throughout the last century, the field of tumor virology has discovered 
groundbreaking findings that helped us to understand the causes of cancer.  In the new era 
of genomics, the techniques like DNA microarray technology, where one can detect changes 
in the expression of several thousand genes simultaneously, further accelerated the process 
of our understanding of cancer.  This helped us in developing molecular markers and gene 
signatures leading to improved and more accurate diagnosis, tumor grading and alternate 
therapeutic methods including targeted therapies. However, the detection of genes or their 
expression by itself does not reflect the dynamics of various processes in the cell.   
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Proteomics is the study of all the proteins expressed by a given cell, tissue, or organism at a 
given time and under specific conditions.  Since the proteins are the functional units of the 
cell, the development of cancer is directly influenced by the protein synthesis, level and their 
interaction with other molecules. It is now understood that cancer development and 
progression is largely due to aberrant signaling pathways in which the entire network of 
proteins play a major role, the proteomics becomes vital to the further advancement of our 
understanding of various cellular processes.  Genomics based studies are not sufficient in 
our desire towards complete understanding of cancer. For example, the analysis of mRNA 
level does not necessarily reflect the protein content in the cell always.  While the formation 
of mRNA by transcription is the first and an important step in gene expression, protein level 
is controlled by other steps like translation and stability of mRNA and protein.  Multiple 
proteins can be formed from a gene due to alternate splicing.  It is predicted that a human gene 
on an average can encode three or more proteins (Wilkins et al., 1996).  Proteins are also 
subjected to post-translational modifications which play a major role in regulating their 
functions by altering their localization, interactions and turnover. It is estimated that the 
proteins can undergo as many as 200 different kinds of modifications (Krishna and Wold, 
1993).  Protein function is also regulated by their localization and interaction with other 
proteins.  By using proteomic approach, it is possible to identify the changes in protein 
modifications, subcellular localization and protein-protein interactions for many proteins 
expressed in a cell.  Proteomics also help in annotation of genome as predicting genes from 
genomic data by using bioinformatics algorithm is not always accurate.  An integration of 
genomic data with proteomic studies is needed to achieve complete annotation of the genome.   
3. Proteomic methods 
3.1 Detection methods 
Conventionally, the protein identification was done by carrying out Edman degradation, a 
chemical method used for the sequencing of amino acids from the N-terminal end of a 
peptide (Edman, 1949).  The limitations of this method are that it is very exhaustive, time 
consuming and requires more protein sample.  Mass spectrometers traditionally used for 
measuring the mass of small molecules became an important and indispensible tool in 
protein identification since the introduction of Matrix-Assisted Laser Desorption/Ionization 
(MALDI) methodology (Karas and Hillenkamp, 1988).   
3.1.1 Mass spectrometer 
Mass spectrometer comprises three principle components: ionization source, analyzer, and 
detector.  Ionization source can be either MALDI or Electrospray Ionization (ESI). In MALDI, 
the analyte is co-crystallized with matrix, which imparts laser energy on analyte and thus 
helps in its ionization.  The ions generated in MALDI are singly charged. In ESI, the analytes in 
aqueous phase are introduced through a fine capillary needle into a high voltage chamber, 
wherein solvent evaporates leaving behind analytes as multiply charged ions. The generated 
ions are then separated based on their mass/charge (m/z) ratio by analyzer.  
Different types of analyzers are Time Of Flight (TOF), quadrupole and Fourier Transform 
Ion Cyclotron Resonance (FT-ICR). The TOF analyzer is commonly used in MALDI based 
mass spectrometry.  In TOF analyzer, an electric field accelerates the ions in a vacuum tube 
and allows to drift towards the detector. Since all the ions posses similar charge, their kinetic 
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energy will be identical.  Thus, the ions are separated merely based on their masses.  The ion 
with least mass will reach the detector first.  In quadrupole mass analyzer, a radio frequency 
(RF) field is created between four parallel metal rods through which ions passes. The paths 
of ions are either stabilized or destabilized selectively by superimposing oscillating electrical 
fields such that ions in a certain range of m/z ratio are allowed to reach the detector at any 
given time.  Thus, quadrupole mass analyzer acts as a mass-selective filter.  In FT-ICR, the 
charged ions experience movement in a fixed magnetic field which is known as ion 
cyclotron resonance wherein the frequency of an ion's cycling is determined by its mass to 
charge ratio.  These ions are excited by radio frequency (RF) signal which produces image 
current measurable by the detector.   
The final component of MS is a detector, which is either an electron multiplier. When the 
ions hit the surface of the detector, the current signal thus produced is recorded and is 
represented as mass spectrum.   
3.1.2 Protein identification using peptide mass finger printing (PMF) and tandem MS 
Most often in proteomics, the protein identification is achieved by MALDI-TOF MS analysis.  
Typically, the protein is digested with trypsin and the resulting peptide mixture is analyzed 
on MALDI, which generates a spectrum with peaks representing singly charged masses of 
peptides.  The list of peptide masses are searched against tryptic peptides generated in silico 
from a database of protein (Pappin et al., 1993) or translated nucleic acid sequences (James et 
al., 1994) to confirm the protein identity.  This process is called as peptide mass finger 
printing.  However, if protein sample contains more than one protein, it may result in 
complex spectra that are less successfully handled by existing algorithms and software.  
Spectral peaks corresponding to peptides with known possible modifications can be 
successfully matched to database peptide sequences if the possibility of the modification is 
specified by the user. However unanticipated modifications will lead to incorrect 
identification of the protein.  In such cases, tandem MS (MS/MS) provides the most 
powerful tool to unambiguously detect protein identity and modification.   
3.2 Separation methods 
3.2.1 Gel based separation methods 
2-dimensional gel electrophoresis (2DE) is probably the first introduced proteomic 
technique and being widely used for a large scale separation and identification of protein(s).  
It was first described and demonstrated by O’ Farrell (O’ Farrell, 1975).  In 1977, Anderson 
and coworkers applied 2DE to separate the plasma proteins (Anderson and Anderson, 
1977).  Since then 2DE technique has been enormously used to profile the proteome of many 
organisms, organelles, cell lines and biological fluids.  This technique separates proteins 
based on two independent properties of the proteins.  In the first step, isoelectric focusing 
(IEF), the proteins are separated according to their isoelectric point.  In the second step, 
proteins are separated based on their molecular weight in sodium dodecyl sulphate 
polyacrylamide gel electrophoresis (SDS-PAGE).  The protein spots are visualized by 
coomasie blue staining or silver staining and the digital images of the gels can be analyzed 
through software to obtain the quantitative information of the protein spots.  The protein 
spot of interest is excised, destained and subjected to tryptic digestion.  The tryptic peptides 
are analyzed in MS to acquire the Peptide Mass Fingerprint (PMF). The peaks in a PMF 
correspond to peptides derived from protein spot excised on a 2D gel.  The peptide mass 
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values are searched against the appropriate database to confirm the identity of the protein 
spot.  But the conventional 2DE based separation and visualization techniques often lack 
reproducibility in proteome separation and sensitivity to detect low abundant proteins.  
In order to improve the conventional 2DE in this respect, Differential gel electrophoresis 
(DIGE) was introduced (Unlu et al., 1997). In DIGE, the two different samples are first 
labeled with fluorescent dyes (Cy3 and Cy5), then mixed together and subjected to DE on a 
single gel.  The gel is subsequently scanned at different wavelengths to generate the images 
corresponding to different samples used in the experiment.  This provides two advantages 
in protein identification: first, the fluorescent labeling is very sensitive and hence it can 
detect even very less abundant proteins; second, the control (Cy3) and test (Cy5) samples 
are separated on a single gel thereby eliminating the gel-to-gel variation and artifacts.  
Therefore, any variation seen between two differentially labeled samples is mostly due to 
actual biological differences.  After the fluorescent images are generated for software based 
analysis, the gel is counter stained with coomassie or silver stain, the spot of interest is 
subjected to MS to confirm its identity.  But, most often, the spots seen by fluorescent stain is 
not visualized by the conventional staining methods. Therefore, the protein spot(s) of 
interest for identification is preferably taken from a preparatory gel run independently.  
When more number of control and test samples are to be analyzed by DIGE, generally a 
common pool consisting equal amounts of all samples is made and labeled with Cy2 dye.  
This Cy2 labeled pool is run along with control (Cy3) and test (Cy5) in every gel as internal 
standard which helps in normalizing variation between gels. 
3.2.2 Non-gel based separation methods 
3.2.2.1 Lable free methods 
Despite the advancements in 2DE, it is no longer effective in situations like identification of 
proteins with low abundance, high hydrophobicity, extreme pI and molecular weight.  To 
overcome these problems, in-solution separation or Liquid Chromatography (LC) method 
was coupled with ESI-MS based identification of proteins. In LC based proteomics, complex 
mixture of proteins are first digested to peptides by proteases, separated by one or more 
dimensions of LC and subjected to tandem MS analysis. The protein identification is 
achieved based on one or more identified peptide sequences. The separation and analysis of 
tryptic peptides rather than the protein is termed as bottom-up approach.  To achieve the 
efficient separation of peptides, the combination of multi-dimensional chromatography has 
been in use and this technique is popularly called as Multidimensional Protein Identification 
Technology (MudPit) (Washburn et al., 2001). MudPit is a most common two-dimensional 
LC separation which combines Strong Cation Exchange (SCX) chromatography with reverse 
phase (RP). The fractions separated by RP are directly injected into online ESI-MS or on 
MALDI target plate for analysis by MS/MS.   
3.2.2.2 Labeling methods 
The combination of protein labeling approaches with LC-based separation coupled to ESI-
MS has greatly facilitated the large scale identification and quantification of the proteins.  
Such a combined approach is called as quantitative proteomics. The different labeling 
techniques include Stable Isotope Labeling of Amino acids in Cell culture (SILAC), Isotope 
Coded Affinity Tag (ICAT), Isobaric Tag for Relative and Absolute Quantification of 
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peptides (iTRAQ) and Proteolytic 18O labeling. These techniques differentially label the 
proteins of two (or more) conditions; this is achieved by metabolic incorporation of 
isotopically distinct amino acids in live cells (SILAC), through chemical labeling of proteins 
with isotopically distinct tags bound to –SH groups (ICAT) or isobaric amine specific tags 
bound to amino groups (iTRAQ) (Figure.1).  
3.2.2.2.1 SILAC 
SILAC involves growing cells under two different conditions (Control Vs Test): one in 
medium containing ‘light’ amino acid and other in ‘heavy’ amino acid containing medium 
(Ong et al., 2002).  Heavy amino acid containing 2H instead of H, or 13C instead of 12C or 15N 
instead of 14N is used.  Incorporation of a heavy amino acid into a peptide results in a 
known mass shift compared with peptide containing light amino acid. For example, a six 
carbon containing amino acid like arginine when labeled with 13C isotope can differentiate a 
given peptide derived from two different conditions by 6 Da mass difference. The protein 
samples of control and test conditions are mixed in equal proportion, subjected to trypsin 
digestion, which selectively cleaves at the carboxyl side of arginine or lysine. The resulting 
peptide mixture is analyzed by LC-MS to generate a MS spectrum wherein each peptide 
appears as a pair with expected mass difference. The relative abundance of a peptide is 
obtained by comparing the intensities of peptides within a pair (Figure.1A).   
3.2.2.2.2 ICAT 
In 1999 Aebersold and co-workers (Gygi et al., 1999) introduced the ICAT method for 
relative quantitation of protein abundance.  ICAT reagent contains three moieties: biotin tag 
to isolate the ICAT labeled peptides, a linker with either eight hydrogen or eight deuterium 
giving an isotope mass difference of 8 Da and cysteine reactive malemide group.  In this 
technique, the complex protein mixtures from two different conditions (Control Vs Test) are 
labeled using heavy and light ICAT reagent such that one condition contains hydrogen 
whereas other contains deuterium giving rise to 8 Da mass difference.  The labeled protein 
samples from two different conditions are mixed equally and subjected to proteolytic 
digestion, thus obtained mixture of peptides are affinity purified using avidin column to 
enrich the labeled peptides. The peptides are analysed by LC-MS to obtain the relative 
abundance of a given protein (Figure.1B).   
3.2.2.2.3 iTRAQ 
In iTRAQ, the peptides derived from different protein samples are labelled with iTRAQ 
tags.  The tag is covalently linked to N-terminal amine group/side chain amine groups of 
peptides. The tag is of 145 Da and consists of three moieties, N-hydroxy succinimide (NHS) 
ester for reaction with primary amine groups on peptides, balance moiety (carbonyl group) 
and reporter moiety.  The reporter moiety may have varying mass like 114, 115, 116 and 117 
Da and hence four different conditions (4-plex) can be analysed and relative quantification 
obtained simultaneously (Ross et al., 2004). The peptides from different conditions are 
labeled with iTRAQ tags which differ in their reporter ions, pooled, fractionated in nano-LC 
and analysed by tandem mass spectrometry.  Due to isobaric mass of iTRAQ tags, the 
peptides appear as single peaks in MS scan. When the iTRAQ-peptides are analysed on 
MS/MS, the tagged peptides dissociates into peptide sequence, a neutral balance moiety 
and reporter ions. The protein identification is achieved by searching the peptide sequence 
against the database(s).  The relative abundance of protein is estimated by the relative peak 
intensity of the liberated reporter ions (Figure.1C).   
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Fig. 1. A. Peptide quantitation using  SILAC method. Cells are grown in “light” and “heavy” arginine containing m
combined and digested with trypsin. The resulting peptide mixture is subjected LC/MS, where in light and heavy
appear as a pair of peaks. The ratio between the light and heavy isotope containing peptides provide the relative ab
mass spectometry is performed to confirm the protein identity. B.  Peptide quantitation using ICAT method. Total
different conditions are differently labeled with “light” and “heavy” ICAT tags. The samples are combined in equal
trypsin and ICAT tagged peptides are enriched by affinity isolation. Then the tagged peptides appear as pair of pe
relative abundance of the peptide is estimated by taking the ratio of relative intensity between “light” and “heavy”
achieved by tandem mass spectometry.  C. Peptide quantitation using iTRAQ method. Total protein mixture from
and modified with isobaric tags on the N-terminus of all peptides. All tagged to peptide groups are mixed togethe
analysis. After fragmentation and peptide identification, the low mass  region of the MS/MS spectrum displays th
fragmentation of the isobaric tag. The ratio of reporter ions in the MS/MS spectrum provides relative abundance o
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3.3 Other proteomic methods 
We describe here briefly about other techniques available for proteomic analysis.  More 
detailed information can be obtained from elsewhere (Angenendt et al., 2006; Diamandis, 
2003; Haab, 2005; Kim et al., 2009; Petricoin et al., 2002). A relatively new proteomic 
technique that is suitable for high-throughput profiling is Surface Enhanced Laser 
Desorption/Ionization-Time-Of-Flight (SELDI-TOF) which combines affinity 
chromatography on a modified surface (surface-enhanced) with MALDI-TOF.  Protein chips 
with different chromatographic surfaces either chemically modified like hydrophobic, 
hydrophilic, cationic, anionic and metal ion or biochemically modified like antibody-
antigen, receptor-ligand and DNA-protein are used to fractionate proteins from complex 
protein mixtures.  In the next step, an energy adsorbing matrix is layered over the protein 
chip and a spectrum will be obtained following laser desorption/ionization.  While SELDI is 
capable of producing protein spectra that can discriminate tumor from normal controls, it 
does not provide the identity of the protein markers involved. SELDI based proteomic 
approach involves a pattern discovery phase wherein a discriminatory peak pattern is 
identified and pattern matching phase in which the identified pattern is validated.   
A powerful chip-based proteomic technique which does not utilize mass spectrometry is 
antibody and protein arrays.  Antibody array essentially utilizes antibodies, which are 
covalently immobilized onto a solid surface like glass slide to capture labeled antigens.  In 
contrast, the protein array contains proteins of interest arrayed on a flat surface. The main 
use of protein array is to detect autoantibodies seen in conditions like autoimmune 
disorders and cancer.  Since the main hurdle in development of protein array is expression 
and purification of proteins, alternate techniques like chemical synthesis, cell-free DNA 
expression or cell-free in situ expression of PCR products are being developed (Angenendt 
et al., 2006). A modification of antibody arrays is bead arrays wherein antibodies are 
immobilized to spherical particles containing integrated reporter fluorescent dyes.  Since the 
reporter dye encodes the identity of capture agent attached to the bead, a multiplex assay 
format is produced by mixing beads with different reporter dyes and capture agents.  
Because of higher sample throughput, bead arrays are particularly suitable for screening 
large number of samples.   
4. Application of proteomics in glioma 
Histological methods relying on microscopic description of glioma helped us not only 
classification and also making therapeutic decisions (Brat et al., 2008). Subjectivity and inter-
observer variations in histopathology may lead to compromise in making choices in 
therapeutic modalities (Brat et al., 2008). In the last two decades, genomics in the form of 
various high throughput techniques helped us enormously not only in increasing our 
understanding of glioma biology but also resulted in the identification of several gene or gene 
signatures for diagnosis, grading and glioma therapy. These findings have not been translated 
into clinic and hence the patient outcome remains low. With requirement of better validated 
robust markers, proteomics appears to be promising in making the lead. We have summarized 
important discoveries in glioma research using various proteomic methods.   
4.1 Glioma tumor tissue and cell line based studies 
Using 2DE, Iwadate et al analyzed 85 tissue samples (52 GBM, 13 AA, 10 DA and 10 normal 
brain samples), and identified 57 protein spots which could be used to differentiate tumors 
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from normal brain tissue (Iwadate et al., 2004).  Out of the differentially regulated protein 
spots, the identity was found for 5 spots by MALDI-TOF and were categorized into various 
biological functions like signal transduction related proteins, molecular chaperones, 
transcription and translation regulators, cell cycle-mediating proteins, extracellular matrix-
related proteins, and cell adhesion molecules.  High levels expression of four proteins-
VREB1, GRP78, RhoA and Rac1 and lower expression of enolase in grade IV tumors 
compared to lower grade tumors was also confirmed by immunohistochemistry.  In another 
attempt to identify differentially expressed proteins between astrocytoma grades, 10 grade 
II and 10 grade IV samples were analyzed by 2DE followed by mass spectrometry, which 
resulted in the identification of 15 differentially expressed proteins (Odreman et al., 2005).   
These findings were subsequently validated by western blotting and immunohistochemcial 
staining. The proteins more highly expressed in glioblastoma multiforme were 
peroxiredoxin 1 and 6, the transcription factor BTF3, and R-B-crystallin, whereas protein 
disulfide isomerase A3, the catalytic subunit of the cAMP-dependent protein kinase, and the 
glial fibrillary acidic protein were increased in low-grade astrocytomas.  Hiratsuka et al used 
six non tumoral samples and five glioma samples (one grade II, two grade III and two grade 
IV) for 2DE and MALDI-TOF spectrometry investigation and identified 11 upregulated 
proteins and 4 down regulated proteins in glioma compared to normal samples (Hiratsuka 
et al., 2003). Northern blotting confirmed the glioma downregulation of SIRT2. Further, 
overexpression of SIRT2 resulted in perturbation of microtubule network and reduced 
colony formation suggesting SIRT2 may act as tumor suppressor in glioma. Ngo et al., used 
a 2D-DIGE based proteomic approach to identify differences in protein expression between 
two glioma cells which differ in their chromosome 1p status (Ngo et al., 2007). The rational 
for this study is that 1p+/- anaplastic oligodendroglioma patients respond better to 
chemotherapeutic agents like procarbazine, 1-(2-chloroethyl)-3-cyclohexyl-l-nitrosourea, 
and vincristine.  Comparison of A172 (1p+/-) and U251 (1p+/+) glioma cell lines identified 
9 spots as differentially regulated proteins, out of which the identity was found by MALDI-
TOF/TOF MS for 18 proteins which included three proteins α-enolase, stathmin and DJ-1 
encoded by 1p region.  Further analysis revealed that decreased stathmin, a microtubule 
associated protein, was found to be associated with loss of heterozygosity, increased 
recurrence-free survival in anaplastic ologidendroglioma patients.  Expression of stathmin 
was also found to correlate inversely with overall survival of nitrsourea treated mice 
carrying xenograft tumors.  On mechanistic front, this group identified an increased mitotic 
arrest in cells with less stathmin expression upon nitrosoureas treatment as potential reason 
for improved patient outcome with 1p+/- anaplastic oligodendroglioma tumors.   
In an effort to identify proteins that could affect sensitivity of glioma cells to chemotherapy, 
Puchades et al., analysed the protein profiles by 2DE of control U87 glioma cells or infected 
with p53 adenovirus or treated with SN38, a topoisomearse 1 inhibitor either alone or in 
combination.  Of many proteins modulated by this treatment, they found galectin1 to be 
down regulated by p53 which is further enhanced by SN38 treatment.  Further investigation 
revealed a high level expression of galectin 1 in glioma cell lines and down regulation of 
galectin 1 sensitized glioma cells to chemotherapy suggesting that galectin 1 could be a 
potential therapeutic target (Puchades et al., 2007). Another interesting review work 
compared systematically many independent glioma proteomic studies and identified 10 
proteins- PHB, Hsp20, serum albumin, epidermal growth factor receptor (EGFR), EA-15, 
RhoGDI, APOA1, GFAP, HSP70 and PDIA3 to be differentially expressed in gliomas 
(Deighton et al., 2010)  
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4.2 Serum and CSF based studies 
Using combination of 2DE and MALDI-TOF MS, Kumar et al.,  analyzed 14 GBM and 6 
normal control sera and identified haptoglobin (Hp) α2 chain as an up regulated serum 
protein in GBM patients (Kumar et al. 2010). GBM-specific upregulation was confirmed by 
ELISA based quantitation of haptoglobin (Hp) in the serum of 99 GBM patients as against 
lower grades (49 grade III/AA; 26 grade II/DA) and 26 normal individuals. Further 
validation done using RT-qPCR on an independent set of tumor and normal brain samples 
and immunohistochemcial staining on a subset of above samples showed an increasing 
levels of Hp transcript and protein respectively with tumor grade and were highest in GBM. 
Further investigation revealed that overexpression of Hp either by stable integration of Hp 
cDNA or exogenous addition of purified Hp to immortalized astrocytes resulted in 
increased cell migration. Conversely, RNAi-mediated silencing of Hp in glioma cells 
decreased cell migration. Mouse melanoma and human glioma cells over expressing Hp 
showed increased tumor growth with decreased mice survival in mouse xenograft model.  
SELDI-TOF analysis of serum samples coupled with artificial neural network (ANN) 
algorithm followed by discriminant analysis identified a fifteen peak pattern which can 
classify low grade (I/II) from high grade (III/IV) tumors with an accuracy of 85.7% (Liu et 
al., 2005). Petrik et al., compared the SELDI-TOF mass spectra derived from 200 serum 
samples that comprised of 58 control subjects and 36 patients with grade II astrocytoma, 15 
with anaplastic astrocytoma, and 91 with glioblastoma and identified a peak with size of 
2.740 kDa showing decreasing intensity with increasing astrocytoma grade (Petrik et al., 
2008). The peak was subsequently identified by tandem MS as B-chain of α2-Heremans-
Schmid glycoprotein (AHSG). This finding was validated by measuring the serum AHSG 
levels using turbidimetry in an independent set of serum samples. More interestingly, 
multivariate Cox proportional hazards model identified serum AHSG levels were to be an 
independent predictor of patient survival with normal levels being associated with 
prolonged survival.  Analysis of cerebrospinal fluid samples from 60 patients comprising 47 
brain tumors and 13 nontumor controls by two independent proteomic techniques, 2DE and 
cleavable ICAT, found an exclusive presence of attractin in grade III and IV astrocytoma 
(Khwaja et al., 2006). High-grade specific upregulation of attractin in CSF was validated by 
western blotting and immunohistochemistry in an independent set of samples. Analysis of 
tumor samples demonstrated the source of high levels seen in CSF as tumors. Finally, this 
study showed the attractin from CSF could induce glioma cell migration suggesting the 
importance of attractin in high invasive nature of high-grade gliomas. Others studies where 
proteomic approaches were used in analysis of serum and CSF of glioma patients are 
reviewed recently (Niclou et al., 2010; Somasundaram et al., 2009). 
5. Conclusions 
Proteomics is certain to become part of important discoveries in glioma as it has already 
become an integral part of glioma research.  Although glioma proteomics research have not 
yielded any breakthrough findings close to becoming an application in clinics, the great 
advances in the proteomic technology in the form of more powerful and sensitive mass 
spectrometers, quantitative proteomic methods like SILAC, ICAT, iTRAQ, and 
improvements in data analysis in the form of sophisticated databases and bioinformatic 
software likely to hasten the biomarker discovery in the years to come.  While gel based 
separation techniques like 2DE or 2D-DIGE will continue to be in use, the label free or 
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labeled quantitative MS methods will take the center stage.  Further, serum biomarker 
discovery field is where proteomic platform is likely to play a major role.  However, one 
major drawback of current proteomic studies is that most of them are of low throughput 
studies having utilized small number of samples. This obviously requires extensive 
validation perhaps using other techniques like ELISA or tissue microarray in large number 
of samples. Prospective validation studies are also needed to confirm the clinical benefit to 
the patients.   
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